Akebia Therapeutics Inc. (AKBA)
1.92
0.01 (0.52%)
At close: Mar 31, 2025, 3:59 PM
1.94
1.05%
After-hours: Mar 31, 2025, 05:44 PM EDT
Akebia Therapeutics Income Statement
| Year | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 |
| Revenue | 160.18M | 194.62M | 292.6M | 213.58M | 295.31M | 335M | 207.74M | 177.98M | 1.53M | n/a | n/a | n/a | n/a |
| Cost of Revenue | 63.18M | 74.15M | 84.8M | 153.39M | 295.91M | 145.34M | 7.68M | 617K | 115.78M | 96K | 23.26M | n/a | n/a |
| Gross Profit | 97M | 120.47M | 207.81M | 60.18M | -601K | 189.66M | 200.06M | 177.37M | -114.25M | -96K | -23.26M | n/a | n/a |
| Operating Income | -50.47M | -46.26M | -63.18M | -265.32M | -376.44M | -286.29M | -178.14M | -79.92M | -136.46M | -61.51M | -37.94M | -15.93M | -8.52M |
| Interest Income | n/a | n/a | 15.69M | 19.95M | 8.92M | 2.19M | 6.15M | 2.8M | 901K | n/a | n/a | n/a | 1.64M |
| Pretax Income | -69.41M | -51.92M | -92.56M | -282.84M | -383.46M | -286.29M | -171.9M | -76.91M | -135.75M | -60.72M | -37.03M | -13.17M | -8.2M |
| Net Income | -69.41M | -51.92M | -106.01M | -244.87M | -349.87M | -279.66M | -171.9M | -76.91M | -135.75M | -60.72M | -37.03M | -13.17M | -8.2M |
| Selling & General & Admin | 106.55M | 100.23M | 141.87M | 174.16M | 153.95M | 149.46M | 87.06M | 27.01M | 22.21M | 18.5M | 12.54M | 5.15M | 2.89M |
| Research & Development | 37.65M | 63.08M | 129.11M | 147.85M | 218.49M | 322.97M | 291.07M | 230.89M | 115.78M | 43.02M | 25.4M | 10.78M | 5.63M |
| Other Expenses | 3.28M | 3.42M | -12.54M | 3.49M | 3.41M | 3.53M | 6.24M | 204K | -188K | 287K | 700K | 1.05M | 1.97M |
| Operating Expenses | 147.47M | 166.73M | 270.99M | 325.5M | 375.84M | 475.95M | 378.2M | 257.9M | 138M | 61.51M | 37.94M | 15.93M | 8.52M |
| Interest Expense | 18.18M | 6.03M | 15.69M | 19.94M | 8.87M | 1.4M | 6.15M | n/a | n/a | 510K | 206K | 703.57K | n/a |
| Selling & Marketing Expenses | n/a | 100.23M | -3.17M | 174.16M | 153.95M | 149.46M | 87.06M | n/a | n/a | n/a | n/a | n/a | n/a |
| Cost & Expenses | 210.65M | 240.88M | 355.78M | 478.9M | 671.75M | 621.29M | 385.88M | 257.9M | 138M | 61.51M | 37.94M | 15.93M | 8.52M |
| Income Tax | n/a | n/a | 13.45M | -37.97M | -33.59M | -6.63M | -28.34M | -2.8M | -901K | -510K | -206K | 1.75M | 1.6M |
| Shares Outstanding (Basic) | 210.95M | 187.47M | 182.78M | 165.95M | 138.46M | 118.4M | 116.89M | 43.5M | 37.72M | 26.47M | 15.41M | 19.27M | 10.13M |
| Shares Outstanding (Diluted) | 210.95M | 187.47M | 182.78M | 165.95M | 138.46M | 118.4M | 116.89M | 43.5M | 37.72M | 26.47M | 15.41M | 19.27M | 10.13M |
| EPS (Basic) | -0.33 | -0.28 | -0.58 | -1.48 | -2.53 | -2.36 | -1.47 | -1.77 | -3.6 | -2.29 | -2.4 | -0.68 | -0.81 |
| EPS (Diluted) | -0.33 | -0.28 | -0.58 | -1.48 | -2.53 | -2.36 | -1.47 | -1.77 | -3.6 | -2.29 | -2.4 | -0.68 | -0.81 |
| EBITDA | -13.72M | -6.87M | -43.26M | -225.96M | -341M | -247.64M | -178.09M | -76.06M | -136.16M | -61.42M | -37.89M | -12.46M | -6.55M |
| Depreciation & Amortization | 36.75M | 37.63M | 35.28M | 36.13M | 33.59M | 36.42M | 2.42M | 617K | 296K | 96K | 49K | 1.28K | 39.16K |